Shuwen Biotech Secures Tens of Millions in Series A+ Funding from Boyi Fund, to Forge Strategic Collaboration with Tasly and Chongqing Pharma

On April 8, 2018, Zhejiang Shuwen Biotech Co., Ltd. (hereinafter referred to as “Shuwen Biotech”) announced the completion of its Series A+ financing round. The amount raised in this round was tens of millions of RMB, with the investor being the Chongqing Boyi Xintian Equity Investment Fund (hereinafter referred to as “Boyi Fund”), which is jointly established and managed by Tasly Holding Group and Chongqing Huayi Group.

Zhejiang Shuwen Biotech Co., Ltd., established in 2010, is a comprehensive biotechnology enterprise integrating the development and sales of medical diagnostic reagents, third-party medical testing services, and pharmaceutical R&D outsourcing services.

The company’s founders and entrepreneurial team include multiple returnee PhDs and nationally renowned experts who previously held management and diagnostic R&D roles at prominent U.S. molecular medical diagnostics companies. They bring extensive experience in managing molecular diagnostics enterprises, possess significant technological advantages, and hold exclusive rights to several proprietary products and patented technologies.

Through international collaboration and the introduction, digestion, and re-innovation of patented technologies, Shuwen Biotech has built a translational platform for innovative medical diagnostics. Currently, the company has established strategic partnerships with more than ten renowned medical institutions and enterprises, including Yale University, the University of Chicago, the Max Planck Institute in Germany, BioNTech SE, and SphingoTec GmbH.

By leveraging independent innovation, the company has secured more than 50 patents and developed nearly 20 first-in-class proprietary novel diagnostic biomarkers and exclusive diagnostic products, covering multiple fields including lung cancer, breast cancer, maternal-fetal medicine, critical care, and population-based health prevention and screening.

The Boyi Fund, the investor in this round, was jointly established by Tasly Holding Group, Chongqing Huayi Pharmaceutical Group, and the Chongqing Industrial Guidance Fund, among other institutions. The fund focuses on pharmaceutical investments and has already invested in over ten high-quality targets across sectors including pharmaceuticals, healthcare, in vitro diagnostics (IVD), and medical devices.

Zhu Yanfei, head of Boyi Fund, stated, “After frequent engagements and several rounds of due diligence with Shuwen Biotech, we firmly believe that it is a company equipped with an advanced biomedical translation platform and industrial base, as well as multiple potential revenue models. This is a rare find in the industry.”

“We are delighted to have gained the recognition of Tasly and Chongqing Huayi Medical & Pharmaceutical Group. Through the investment by Boyi Fund, Shuwen Biotech will enter into a strategic partnership with Tasly Holding and Chongqing Pharmaceutical, both of which possess extensive resources in the healthcare industry and strong channel advantages. This collaboration will accelerate the commercialization of Shuwen Biotech’s numerous diagnostic products and technologies,” said Zhang Yizhe, Founder and General Manager of Shuwen Biotech. “At the same time, it will provide support for Shuwen Biotech to further expand its international cooperation and build a platform for the innovative translation of medical diagnostics.”